CMIC was founded in 1992 as the first contract research organization (CRO) in Japan. To enable pharmaceutical companies to develop better medicine sooner, we expanded our solutions to include contract development and manufacturing (CDMO), site support, and market solutions, supporting global companies to bring highly desired treatments to the Japanese market, to consult and conduct Asia clinical trials, or to bridge drug development and manufacturing needs between the US and Japan.

CMIC recently started a new stage by entering the healthcare arena. Leveraging our vast experience and expertise in the medical industry, we offer solutions using a new ecosystem of healthcare to support the individuals and local governments.

We strive to be a Personal Health Value Creator (PHVC) to meet our global customers’ needs in the U.S., Japan, and broader Asia.



Learn from industry experts on the market insights and tips for your successful clinical development in Japan and China.

The APAC market has a large treatment naïve population, and has shown improvements in the regulatory environment. Discover insights and tips for successful clinical development in the APAC region

The COVID-19 global pandemic took the world by storm, disrupting several industries and our global supply chains. Learn why having a contingency plan and proactively planning gives a company a competitive edge. 

Explore how to navigate the regulatory hurdles and accelerate oncology clinical trials by making the right connections within the oncology field.

Explore why mRNA therapeutics has already become a focus area with joint efforts from pharmaceutical companies worldwide.

In recent years, attempts to utilize messenger RNA (mRNA) for medicines are actively increasing worldwide. Since mRNA can produce any protein in theory, it is expected to have a wide range of clinical applications.


CMIC Group

Hamamatsucho Building, 1 Chome-1-1 Shibaura

Minato City, Tokyo, 105-0023


Contact: inquiriesUSA@cmicgroup.com